All In Biotech

Drug Trial Radar · NCT03769090

A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma

A Long-term, Randomized, Double-blind, Multicenter, Parallel-group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT007 Administered as Needed in Response to Symptoms in Symptomatic Adults and Children 4 Years of Age or Older With Asthma

Last checked: Nov 19, 2026Latest source record: Sep 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,132 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,132

Actual

Start

Dec 13, 2018

Primary completion

Aug 19, 2021

Study completion Feb 7, 2022

Sponsor

Lead sponsor
Bond Avillion 2 Development LPIndustry
Sponsor type
Industry
First posted
Dec 7, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, multicenter, parallel-group, variable-length study to compare 2 doses of BDA MDI (PT027) with AS MDI (PT007) on the time to first severe asthma exacerbation in adult, adolescent, and pediatric subjects with moderate to severe asthma.

Conditions

  • Asthma

Interventions

  • Budesonide/albuterol sulfate metered-dose inhaler 160/180 μgCombination product

    Budesonide/albuterol sulfate combination inhalation aerosol

  • Budesonide/albuterol sulfate metered-dose inhaler 80/180 μgCombination product

    Budesonide/albuterol sulfate combination inhalation aerosol

  • Albuterol sulfate metered-dose inhaler 180 μgDrug

    Albuterol sulfate inhalation aerosol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With a Severe Asthma Exacerbation EventTime frame: From randomization up to a discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.

Locations

345 sites in 11 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Huntsville, Alabama

  • Research Site

    Mobile, Alabama

  • Research Site

    Montgomery, Alabama

  • Research Site

    Scottsboro, Alabama

  • Research Site

    Sheffield, Alabama

  • Research Site

    Tuscumbia, Alabama

  • Research Site

    Glendale, Arizona

  • Research Site

    Peoria, Arizona

  • Research Site

    Scottsdale, Arizona

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Bakersfield, California

  • Research Site

    Bellflower, California

  • Research Site

    Canoga Park, California

  • Research Site

    Encinitas, California

  • Research Site

    Hawthorne, California

  • Research Site

    Long Beach, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Newport Beach, California

  • Research Site

    Rancho Cucamonga, California

  • Research Site

    Redwood City, California

  • Research Site

    Sacramento, California

  • Research Site

    San Diego, California

  • Research Site

    San Francisco, California

  • Research Site

    San Jose, California

  • Research Site

    Westminster, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Denver, Colorado

  • Research Site

    Denver, Colorado

  • Research Site

    Denver, Colorado

  • Research Site

    Waterbury, Connecticut

  • Research Site

    Aventura, Florida

  • Research Site

    Boynton Beach, Florida

  • Research Site

    Cape Coral, Florida

  • Research Site

    Clearwater, Florida

  • Research Site

    Clearwater, Florida

Showing 40 of 345 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.